Swedish Orphan Biovitrum
Solna · Founded 1988
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. It offers drugs for the treatment of rare and life-threatening diseases, such as cardiology, diseases affecting immunocompromised patients, genetic disorders, haematology, infectious diseases, metabolic disorders, oncology, palliative care, poison control, respiratory diseases, and urology.
Company Facts
- Founded: 1988
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1M – $10M
- Total funding: $826.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2024)
- Ticker: sto:SOBI
- Website: sobi.comen
- Phone: (468)697-2000
Industries & Categories
Biotechnology, Genetics, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/swedish-orphan-biovitrum-71808 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.